In patients with type 2 diabetes and CVD, empagliflozin reduced incident or worsening nephropathy at 3.1 y.

@article{Patel2016InPW,
  title={In patients with type 2 diabetes and CVD, empagliflozin reduced incident or worsening nephropathy at 3.1 y.},
  author={Tejas I. Patel},
  journal={Annals of internal medicine},
  year={2016},
  volume={165 8},
  pages={JC39}
}
Outcomes: Main outcome was a component of a prespecified composite secondary outcome: incident or worsening nephropathy (progression to macroalbuminuria, serum creatinine level doubling and eGFR ≤ 45 mL/min/1.73 m, renal replacement therapy initiation, or death due to renal disease). Other outcomes included components of incident or worsening nephropathy… CONTINUE READING